Jul. 4 at 3:28 PM
$CCCC C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following which the stock rose more than 13%. The Street expects more than 158% upside from the current level, making C4 one of the BBest Rising Penny Stocks to Buy According to Wall Street Analysts.
